| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.22 | 4e-09 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.26 | 4e-08 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.25 | 1e-07 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.18 | 2e-07 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.18 | 2e-07 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.25 | 3e-07 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.15 | 9e-06 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.15 | 1e-05 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-05 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.14 | 3e-05 |